Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Cartherics Receives $300K G-Rex Grant to Advance Cancer Cell Therapy Manufacturing

Roche Revolutionizes Mass Spectrometry Diagnostics with Launch of cobas® Mass Spec Solution

Complete Genomics Partners with Eurofins Clinical Enterprise to Expand Sequencing Service Offerings

NeuroKaire Secures $10M to Transform Precision Medicine in Psychiatry and Neurology

Redcliffe Labs Announces Leadership Transition to Drive Healthcare Accessibility

Home
/
update
/
details

Illumina Unveils Expanded Oncology Offerings for NovaSeq X Series Customers

NextEdge Admin

05 Aug 2024

2 min 36 sec

Illumina Inc. , a global leader in DNA sequencing technologies, has expanded its oncology offerings for NovaSeq™ X Series customers. The newly verified high-throughput version of TruSight™ Oncology 500 (TSO 500 HT) and the updated TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2) liquid biopsy assay are now available. These assays enhance oncology research by enabling comprehensive genomic profiling (CGP) of tissue and liquid biopsy samples with improved sequencing economics, faster run times, and larger batch sizes on the NovaSeq X Series.

Everett Cunningham, Illumina’s chief commercial officer, highlighted the significance of these advancements in driving precision oncology forward. CGP assesses hundreds of genes and immuno-oncology biomarkers from a single sample, aiding therapy selection research and aligning with professional oncology guidelines.

TSO 500 HT on the NovaSeq X Series offers increased throughput and cost efficiencies compared to the NovaSeq 6000 System. Illumina plans to extend TSO 500 HT to the NextSeq 1000 and NextSeq 2000 Systems later this quarter. TSO 500 ctDNA v2 on the NovaSeq X Series delivers a faster, more sensitive, and streamlined liquid biopsy workflow, enabling solid tumor therapy selection research from minimally invasive blood samples.

Laura Knight, global VP of Genomic Services at Almac Diagnostic Services, praised the availability of TSO 500 ctDNA v2 on the NovaSeq X Plus platform for advancing molecular analysis of blood-based biomarkers. The assay offers transformative sequencing economics, a 40% reduction in run times, and sustainable logistics with ambient temperature shipping for consumables. These improvements enable Almac to accelerate oncology research and diagnostic development, marking a significant advancement in precision medicine.